Bursa Uludağ Üniversitesi Açık Erişim Sistemi
Bursa Uludağ Üniversitesinin araştırma çıktılarının yer aldığı açık erişim sistemidir.
Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/28552| Başlık: | Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study |
| Yazarlar: | Atahan, Lale Yıldız, Ferah Cengiz, Mustafa Kaplan, Bünyamin Özkan, Metin Yazıcı, Gözde Gündoğ, Mete Haydaroğlu, Ayfer Korcum, Aylin Fidan Şengöz, Meriç Dinçer, Maktav Akmansu, Müge Hayran, Mutlu Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı. Engin, Kayıhan 6701768798 |
| Anahtar kelimeler: | Bone metastasis Breast cancer Radiotherapy Zoledronic acid In-vitro Skeletal complications Multifraction radiotherapy Bisphosphonates inhibit Trial Carcinoma Cells Apoptosis Adhesion Single Oncology Health care sciences & services Rehabilitation |
| Yayın Tarihi: | Haz-2010 |
| Yayıncı: | Springer |
| Atıf: | Atahan, L. vd. (2010). "Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study". Supportive Care in Cancer, 18(6), 691-698. |
| Özet: | In this prospective study, the efficacy and safety of radiotherapy combined with zoledronic acid was evaluated. Breast cancer patients with painful bone metastases were randomized to either high- or reduced-dose radiotherapy. All patients received zoledronic acid (4 mg) every 28 days from the beginning of radiotherapy. Analgesic and pain scores in addition to visual analog score (VAS) for treatment satisfaction and whole-body bone scintigraphy were evaluated. No significant differences could be found in analgesic or pain scores and bone scintigraphy results between the groups. Our results suggest that reduced-dose radiotherapy produces similar response rates and response durations when used concomitantly with zoledronic acid. |
| URI: | https://doi.org/10.1007/s00520-009-0663-x https://link.springer.com/article/10.1007/s00520-009-0663-x http://hdl.handle.net/11452/28552 |
| ISSN: | 0941-4355 1433-7339 |
| Koleksiyonlarda Görünür: | Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.